Gregory Perry

Director of Finance/CFO at MERUS N.V.

Net worth: - $ as of 2024-03-30

63 year

100 connections

Health Technology

Commercial Services

Miscellaneous

Active connections

Name	Gender	Age	Linked companies	Collaboration
Mark Iwicki	M	57	KALA BIO, INC. MERUS N.V.	9 years
Bill Lundberg	M	60	MERUS N.V.	5 years
Peter Silverman	M	46	MERUS N.V.	7 years
Howard Rosen	M	66	KALA BIO, INC.	10 years
Susan Graf	F	52	FINCH THERAPEUTICS GROUP, INC.	3 years
Chris W. Shumway	M	58	FINCH THERAPEUTICS GROUP, INC.	4 years
Mary Reumuth	F	48	KALA BIO, INC.	10 years
Eric Trachtenberg	M	51	KALA BIO, INC.	6 years
Anand Mehra	M	48	MERUS N.V.	9 years
Andrew Koven	M	66	KALA BIO, INC.	7 years
Joseph J. Kenny	M	-	IMMUNOGEN, INC.	15 years
Todd Bazemore	M	53	KALA BIO, INC.	7 years
Victor Sandor	M	57	MERUS N.V.	5 years
Sherri L. Spear	F	-	MERUS N.V.	-
Marjan Farid	M	50	KALA BIO, INC.	2 years
Theresa Wingrove	M	66	IMMUNOGEN, INC.	13 years
Mark Blumenkranz	M	73	KALA BIO, INC.	3 years
Charles Myers	M	70	KALA BIO, INC.	3 years
Domenic J. Ferrante	M	58	FINCH THERAPEUTICS GROUP, INC.	5 years
Paolo Pucci	M	63	MERUS N.V.	4 years
Len Kanavy	M	62	MERUS N.V.	6 years
Ashley Pereira	M	-	MERUS N.V.	3 years
Shannon Campbell	F	-	MERUS N.V.	2 years
Cecilia Anna Wilhelmina Geuijen	M	56	MERUS N.V.	3 years
Kathleen Farren	F	-	MERUS N.V.	-
Andrew Joe	M	58	MERUS N.V.	4 years
Ernesto Wasserman	M	-	MERUS N.V.	8 years
Alexander Berthold Hendrik Bakker	M	57	MERUS N.V.	14 years
Harry Shuman	M	-	MERUS N.V.	-
Hannah Deresiewicz	F	-	KALA BIO, INC.	-
Liu Hui	M	51	MERUS N.V.	9 years
John Heffernan	M	-	OCATA THERAPEUTICS INC	9 years
Maxine Gowen	M	66	MERUS N.V.	3 years
Darius Kharabi	M	45	KALA BIO, INC.	3 years
John de Kruif	M	60	MERUS N.V.	17 years
Romulus Brazzell	M	71	KALA BIO, INC.	11 years
Matthew Nelson	M	-	FINCH THERAPEUTICS GROUP, INC.	3 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Christopher McNulty	M	47	INVIVO THERAPEUTICS HOLDINGS CORP.	5 years
Ton Logtenberg	M	65	MERUS N.V.	16 years
Mitchel Sayare	M	76	IMMUNOGEN, INC.	25 years
Gary H. Rabin	M	58	OCATA THERAPEUTICS INC	7 years
Mary Szela	F	60	NOVELION THERAPEUTICS INC. AEGERION PHARMACEUTICALS, INC.	1 years
Robert Langer	M	75	OCATA THERAPEUTICS INC KALA BIO, INC.	9 years
Donald Stern	M	78	AEGERION PHARMACEUTICALS, INC. NOVELION THERAPEUTICS INC.	4 years
Andrew Noh	M	-	FINCH THERAPEUTICS GROUP, INC.	4 years
Masao Yoshida	M	-	OCATA THERAPEUTICS INC	-
Jay Duker	M	66	CARISMA THERAPEUTICS, INC.	8 years
Michael Heffernan	M	59	OCATA THERAPEUTICS INC	4 years
Marc Blaustein	M	61	FINCH THERAPEUTICS GROUP, INC.	2 years
Paul Wotton	M	63	OCATA THERAPEUTICS INC	2 years
Marc Beer	M	59	AEGERION PHARMACEUTICALS, INC.	5 years
Wendy Dixon	M	68	CARISMA THERAPEUTICS, INC.	6 years
Edward Myles	M	52	OCATA THERAPEUTICS INC	3 years
Michael Dennis Price	M	66	NOVELION THERAPEUTICS INC.	3 years
William Heiden	M	64	Elixir Pharmaceuticals, Inc. Elixir Pharmaceuticals, Inc. Investment Trusts/Mutual FundsMiscellaneous Elixir Pharmaceuticals, Inc. operates as a holding company with interest in manufacturing and developing biopharmaceutical products for the treatment of metabolic diseases such as diabetes and obesity. The company was founded by Leonard Guarente, Cynthia J. Kenyon, Cindy Bayley, Louis Kunkel, Annibale Puca, and Thomas Perls in 1999 and is headquartered in Cambridge, MA.	4 years
Paulina Hill	M	42	KALA BIO, INC.	1 years
Jeffrey Hackman	M	62	NOVELION THERAPEUTICS INC.	1 years
Samuel Hamood	M	56	FINCH THERAPEUTICS GROUP, INC.	-
Mary Weger	F	65	AEGERION PHARMACEUTICALS, INC.	-
Linda Friedman	F	-	OCATA THERAPEUTICS INC	-
Cameron Wheeler	M	45	CARISMA THERAPEUTICS, INC.	-
Nicholas Haft	M	35	FINCH THERAPEUTICS GROUP, INC.	3 years
Joseph Vittiglio	M	52	FINCH THERAPEUTICS GROUP, INC.	2 years
William T. Andrews	M	60	AEGERION PHARMACEUTICALS, INC.	4 years
Barry Gertz	M	72	CARISMA THERAPEUTICS, INC.	-
Zain Kassam	M	42	FINCH THERAPEUTICS GROUP, INC.	4 years
Mark Throsby	M	57	MERUS N.V.	12 years
Ben Harshbarger	M	55	AEGERION PHARMACEUTICALS, INC.	4 years
Joanne Viney	M	58	FINCH THERAPEUTICS GROUP, INC.	-
Remi A. Menes	M	-	NOVELION THERAPEUTICS INC. AEGERION PHARMACEUTICALS, INC.	1 years
Sarah Kiely	F	-	IMMUNOGEN, INC.	7 years
Mark Dipaolo	M	53	NOVELION THERAPEUTICS INC.	1 years
Jillian Connell	F	-	MERUS N.V.	-
David Warren Carter	M	84	IMMUNOGEN, INC.	14 years
Tamara Joseph	F	61	Transkaryotic Therapies, Inc. Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.	1 years
Kristine Peterson	F	64	IMMUNOGEN, INC.	12 years
Howard H. Pien	M	66	IMMUNOGEN, INC.	9 years
Dean Mitchell	M	68	IMMUNOGEN, INC.	12 years
Paul Chaney	M	66	CARISMA THERAPEUTICS, INC.	4 years
Zohar Loshitzer	M	67	OCATA THERAPEUTICS INC	5 years
Anne Cook	F	62	AEGERION PHARMACEUTICALS, INC.	4 years
Suzanne Bruhn	M	60	NOVELION THERAPEUTICS INC.	3 years
Mark Levin	M	73	CARISMA THERAPEUTICS, INC.	6 years
Robert Tepper	M	68	KALA BIO, INC.	9 years
Doug Treco Treco	M	66	Transkaryotic Therapies, Inc. Transkaryotic Therapies, Inc. Miscellaneous Commercial ServicesCommercial Services Transkaryotic Therapies, Inc. (TKT) was a biopharmaceutical company with a major focus on developing products for the treatment of rare diseases. The company is used to markets one product, Replagal™, for the treatment of Fabry disease in the European Union and other countries, and was developing products for Hunter syndrome and Gaucher disease. The company was located in Cambridge, MA.	17 years
Noubar Afeyan	M	60	CARISMA THERAPEUTICS, INC.	6 years
Alan C. Shapiro	M	78	OCATA THERAPEUTICS INC	11 years
Mark Goldberg	M	69	IMMUNOGEN, INC.	13 years
Mark Corrigan	M	66	NOVELION THERAPEUTICS INC.	2 years
Robert Paull	M	47	KALA BIO, INC.	-
Suzanne M. Cadden	F	64	IMMUNOGEN, INC.	-
Raj Shah	M	46	KALA BIO, INC.	6 years
Kevin Kotler	M	53	NOVELION THERAPEUTICS INC.	2 years
Lionel Carnot	M	56	MERUS N.V.	8 years
David J. Aubuchon	M	-	AEGERION PHARMACEUTICALS, INC.	-
Gregory Grunberg	M	51	KALA BIO, INC.	7 years
John Paul de Koning	M	55	MERUS N.V.	10 years
Anne Marie Conway	F	-	FINCH THERAPEUTICS GROUP, INC.	-
Peter J. Williams	M	69	IMMUNOGEN, INC.	8 years
Susan L. Coultas	M	-	KALA BIO, INC.	6 years

Statistics

Country	Connections	% of total
United States	71	71.00%
Netherlands	24	24.00%
Canada	9	9.00%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections